CL2003002756A1 - Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. - Google Patents

Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.

Info

Publication number
CL2003002756A1
CL2003002756A1 CL200302756A CL2003002756A CL2003002756A1 CL 2003002756 A1 CL2003002756 A1 CL 2003002756A1 CL 200302756 A CL200302756 A CL 200302756A CL 2003002756 A CL2003002756 A CL 2003002756A CL 2003002756 A1 CL2003002756 A1 CL 2003002756A1
Authority
CL
Chile
Prior art keywords
compound
treatment
purrolidines
defenilmetil
carbamoil
Prior art date
Application number
CL200302756A
Other languages
English (en)
Inventor
Cross Peter Edward Dr Macke Dr
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2003002756(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CL2003002756A1 publication Critical patent/CL2003002756A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

ANTAGONISTA DE RECEPTORES MUSCARINICOS DE PIRROLIDINA, PARTICULARMENTE UTILES EN EL TRATAMIENTO DEL SINDROME DE INTENSTINO IRRITABLE DE FORMULA; Y SUS SALES FARMACEUTICAMENTE ACEPTABLES EN LAS CUALES Y ES UNA CONEXION DIRECTA -CH2-, -(CH2)2-, CH2O- O -CH2S- R ES -CN O -CONH2; DONDE X Y X1 SON CADA UNO INDEPENDIENTEMENTE O O CH2; M ES 1, 2 O 3; Y HET ES PIRIDILO, PIRAZINILO, TIENILO.
CL200302756A 1989-03-17 2003-12-26 Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. CL2003002756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents

Publications (1)

Publication Number Publication Date
CL2003002756A1 true CL2003002756A1 (es) 2005-02-11

Family

ID=10653525

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302756A CL2003002756A1 (es) 1989-03-17 2003-12-26 Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.

Country Status (37)

Country Link
US (1) US5096890B1 (es)
EP (1) EP0388054B1 (es)
JP (2) JPH0764809B2 (es)
KR (2) KR920008166B1 (es)
CN (1) CN1023007C (es)
AT (1) ATE96783T1 (es)
AU (1) AU614224B2 (es)
BA (1) BA98300A (es)
CA (1) CA2012295C (es)
CL (1) CL2003002756A1 (es)
CY (2) CY1812A (es)
CZ (1) CZ280053B6 (es)
DD (1) DD292911A5 (es)
DE (2) DE122005000022I2 (es)
DK (1) DK0388054T3 (es)
EG (1) EG18951A (es)
ES (1) ES2060020T3 (es)
FI (1) FI95573C (es)
GB (1) GB8906166D0 (es)
HK (1) HK130294A (es)
HU (2) HU217433B (es)
IE (1) IE62515B1 (es)
IL (1) IL93694A (es)
LU (1) LU91161I2 (es)
MX (1) MX9319890A (es)
MY (1) MY105527A (es)
NL (1) NL300191I2 (es)
NO (2) NO176316C (es)
NZ (1) NZ232958A (es)
PL (1) PL164136B1 (es)
PT (1) PT93443B (es)
RU (2) RU1833374C (es)
SG (1) SG143394G (es)
SK (1) SK278434B6 (es)
UA (1) UA18263A (es)
YU (1) YU47587B (es)
ZA (1) ZA901982B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
WO1993022309A1 (en) * 1992-04-23 1993-11-11 Merrell Dow Pharmaceuticals Inc. 4-imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
BR9508436A (pt) * 1994-07-27 1998-07-14 Procter & Gamble Dihidro benzofurando e compostos correlacionados úteis como agentes anti-inflamatórios
US5674891A (en) * 1994-07-27 1997-10-07 The Procter & Gamble Company Dihydrobenzothiophene compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
WO1998024431A1 (fr) * 1996-12-02 1998-06-11 Kyorin Pharmaceutical Co., Ltd. Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
ATE418534T1 (de) * 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
EP1441706A2 (en) * 2001-11-05 2004-08-04 Pharmacia & Upjohn Company Antimuscarinic aerosol
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
WO2004004629A2 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
ATE396969T1 (de) 2002-07-31 2008-06-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen
WO2004014363A1 (en) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089363A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EP1622606A1 (en) * 2003-04-15 2006-02-08 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds and their use as antimuscarinic agents
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
EP1725525A1 (en) * 2004-03-11 2006-11-29 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007076158A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for preparing darifenacin hydrobromide
AR062676A1 (es) * 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
WO2008076269A2 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
JP5528817B2 (ja) * 2007-02-23 2014-06-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用な第四級アンモニウムジフェニルメチル化合物
WO2008126106A2 (en) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2008152497A1 (en) * 2007-06-15 2008-12-18 Medichem, S.A. Method for determining enantiomeric purity of darifenacin and intermediates
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (en) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Improved process for producing darifenacin
CN101983187A (zh) * 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
SG176056A1 (en) 2009-05-15 2011-12-29 Redx Pharma Ltd Redox drug derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
EP0235463A3 (en) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
IL78939A (en) * 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds

Also Published As

Publication number Publication date
CN1023007C (zh) 1993-12-08
CZ280053B6 (cs) 1995-10-18
EP0388054B1 (en) 1993-11-03
AU614224B2 (en) 1991-08-22
HK130294A (en) 1994-12-02
GB8906166D0 (en) 1989-05-04
DE122005000022I1 (de) 2005-08-04
CN1045580A (zh) 1990-09-26
FI95573B (fi) 1995-11-15
UA18263A (uk) 1997-12-25
JPH02282360A (ja) 1990-11-19
ATE96783T1 (de) 1993-11-15
NL300191I2 (nl) 2005-08-01
KR900014367A (ko) 1990-10-23
NL300191I1 (nl) 2005-07-01
DD292911A5 (de) 1991-08-14
CY2005005I1 (el) 2010-07-28
PT93443B (pt) 1996-02-29
FI901333A0 (fi) 1990-03-16
JPH0764809B2 (ja) 1995-07-12
NO2005008I2 (no) 2006-11-27
YU47587B (sh) 1995-10-24
HU211640A9 (en) 1995-12-28
DK0388054T3 (da) 1993-12-06
EG18951A (en) 1994-03-30
NO901241D0 (no) 1990-03-16
AU5140290A (en) 1990-09-20
IL93694A (en) 1994-08-26
CY1812A (en) 1995-10-20
SK129590A3 (en) 1997-05-07
KR920008166B1 (ko) 1992-09-24
CZ129590A3 (en) 1995-05-17
MY105527A (en) 1994-10-31
US5096890A (en) 1992-03-17
PL164136B1 (pl) 1994-06-30
ES2060020T3 (es) 1994-11-16
HU217433B (hu) 2000-01-28
CY2005005I2 (el) 2010-07-28
DE122005000022I2 (de) 2006-02-02
NO176316C (no) 1995-03-15
DE69004302T2 (de) 1994-02-24
DE69004302D1 (de) 1993-12-09
PT93443A (pt) 1990-11-07
IL93694A0 (en) 1990-12-23
MX9319890A (es) 1993-08-01
US5096890B1 (en) 1995-03-28
ZA901982B (en) 1991-10-30
YU52790A (sh) 1992-07-20
CA2012295A1 (en) 1990-09-17
IE900955L (en) 1990-09-17
NZ232958A (en) 1992-05-26
SG143394G (en) 1995-01-13
NO176316B (no) 1994-12-05
HUT58313A (en) 1992-02-28
EP0388054A1 (en) 1990-09-19
RU1833374C (ru) 1993-08-07
FI95573C (fi) 1996-02-26
KR960015142B1 (ko) 1996-11-01
CA2012295C (en) 1996-11-12
JPH07149640A (ja) 1995-06-13
NO2005008I1 (en) 2005-04-11
IE62515B1 (en) 1995-02-08
SK278434B6 (en) 1997-05-07
HU901580D0 (en) 1990-06-28
LU91161I2 (fr) 2005-06-13
BA98300A (bs) 2001-09-14
NO901241L (no) 1990-09-18
RU2015965C1 (ru) 1994-07-15

Similar Documents

Publication Publication Date Title
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
DE69618231T2 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
DE69011318T2 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
KR960013371A (ko) 약학적 혼합물
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ATE277893T1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
UY26329A1 (es) Antagonistas de los receptores de vitronectina
ES2164168T3 (es) Antagonistas de receptores de fibrinogeno que tienen residuos de beta-aminoacido sustituidos y composiciones farmaceuticas que comprenden los mismos.
DE69322177D1 (de) 8-(1-Aminocycloalkyl)-1,3-Dialkylxanthinderivate als Antagonisten von Adenosinrezeptoren
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
ATE109483T1 (de) Alpha-adrenergische rezeptorantagonisten.
ECSP982623A (es) Derivados del 2-( 4-aril - o heteroaril - piperazin -1- ilmetil) -1h-indol